探索减低剂量预处理亲缘间单倍体非体外去T细胞外周血造血干细胞移植（RIC-RHNT-PBSCT）技术治疗恶性血液病的方法及其可行性。针对那些年龄较大或体质较弱不适合做清髓性移植，且又无法找到HLA全相合供者的恶性血液病患者，我们设计了FAB方案作为预处理方案，采用经G-CSF动员、体外不去T细胞的供者高剂量外周血造血干细胞作为移植物进行RIC-RHNT-PBSCT，按MNC12～15×10^8/kg、15.1～20×10^8/kg分为2组，对移植后植入率、急性移植物抗宿主病发生及临床疗效进行研究，同时对移植早期免疫功能及共刺激分子的变化特点进行研究，以期成功建立独特的RIC-RHNT-PBSCT模式，使更多的患者受益。

Explore clinical efficiency and feasibility of reduced-intensity conditioning regimen to related HLA-haploidentical non T cell-depleted in vitro peripheral hematopoietic stem cell transplantation(RIC-RHNT-PBSCT) for hematologic malignancies.For those patients who are elder or weak, not suitable for myeloablative conditioning regimen, and don't have HLA-matched donor, we design the RIC-RHNT-PBSCT, which use FAB as RIC regimen, and with G-CSF mobilizated non T cell-depleted of donor high-dose peripheral blood stem cell in vitro as graft source. According to the count of MNC, patients are divided into two groups：group A(12～15×10^8/kg) and group B (15.1～20×10^8/kg), We research engrufment ,acute graft versus host disease and clinical efficiency ; immune reconstruction and varying characteristics of co-stimulatory molecular are studied simultaneously. Hoping to establish an unique RIC-RHNT-PBSCT for curing more patients.